Work

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Year: 2020

Type: article

Source: Blood

DOI: 10.1182/blood-2020-134039

Authors: Claudia Lebedinsky, Stephen P. Anthony, Golam Mohi, Huyuan Yang, Jian Mei, Edgar Braendle

Institutions: Sumitomo Dainippon Pharma (Japan), Sumitomo Dainippon Pharma (United States), University of Virginia

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097709169

FWCI: 0.22

Cites:

Cited by: 3

Related to: 10